Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent human papillomavirus recombinant vaccine (types 6, 11, 16, 18)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent human papillomavirus recombinant vaccine (types 6, 11, 16, 18), marketed as Gardasil, is a prophylactic vaccine designed to prevent infections caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18. It is composed of highly purified virus-like particles (VLPs) derived from the major capsid L1 protein of these four HPV types. These VLPs are non-infectious as they lack viral DNA, but they effectively stimulate the body's immune system to produce antibodies, thereby conferring immunity against future HPV infections. Developed by Merck & Co., this vaccine is indicated for the prevention of various HPV-related diseases, including cervical, vulvar, vaginal, and anal cancers, as well as genital warts and precancerous or dysplastic lesions caused by the targeted HPV types.
- Brand names
- Gardasil
- Other names
- Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinantquadrivalent HPV vaccine
02
Targets
HPV18 (Human Papillomavirus type 18)HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV6 (Human papillomavirus type 6 virion)
Beyond the preview
Go deeper on quadrivalent human papillomavirus recombinant vaccine (types 6, 11, 16, 18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent human papillomavirus recombinant vaccine (types 6, 11, 16, 18).